Investors Sue Biopharma Co. After Clinical Trial Data Toss

By Emilie Ruscoe · January 22, 2024, 9:30 PM EST

Biopharmaceutical company BioVie and three of its executives are facing an investors' proposed class action after "suspected coordinated improprieties" led the company to toss data for over 80% of the subjects...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

IN RE BIOVIE INC. SECURITIES LITIGATION

Case Number

Court

Nevada

Nature of Suit

Securities/Commodities

Date Filed

January 19, 2024

Recent Articles By Emilie

November 05, 2024
Bright Health Beats Investor Suit Over COVID-19 Costs
October 30, 2024
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes
October 28, 2024
Moderna Brass Hit With Investor Suit Over RSV Shot Claims
October 22, 2024
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
October 16, 2024
Pharma Co. Contractor Settles SEC Insider Trading Claim
September 24, 2024
Biotech RenovaCare Investors Seek OK Of $2M Deal
September 03, 2024
Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit
August 02, 2024
Health Tech Co. Beats Investor Data Platform Fraud Claim
July 15, 2024
Ex-Pfizer Worker Seeks No Time For Paxlovid Insider Trading
May 20, 2024
Teladoc Faces Suit Over Mental Health Platform's Losses